Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IONS
  • CUSIP: 46433010
Key Metrics:
  • Previous Close: $36.20
  • 50 Day Moving Average: $32.54
  • 200 Day Moving Average: $32.40
  • 52-Week Range: $19.59 - $65.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -35.84
  • P/E Growth: -0.80
  • Market Cap: $4.41B
  • Outstanding Shares: 120,919,000
  • Beta: 2.1
Profitability:
  • Net Margins: -128.94%
  • Return on Equity: -126.88%
  • Return on Assets: -25.00%
Debt:
  • Debt-to-Equity Ratio: 3.63%
  • Current Ratio: 6.28%
  • Quick Ratio: 6.21%
Additional Links:
Companies Related to Ionis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $38.78 (7.12% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
DateFirmActionRatingPrice TargetDetails
9/28/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details
9/26/2016Piper Jaffray Cos.Reiterated RatingOverweight$46.00View Rating Details
9/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
8/13/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
8/11/2016Leerink SwannReiterated RatingHold$36.00View Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00View Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00View Rating Details
8/1/2016BMO Capital MarketsBoost Price TargetMarket Perform$25.00 -> $40.00View Rating Details
8/1/2016Needham & Company LLCBoost Price TargetBuy$55.00 -> $64.00View Rating Details
7/15/2016Jefferies GroupReiterated RatingUnderperform$12.00View Rating Details
5/29/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$65.00 -> $48.00View Rating Details
6/22/2015Deutsche Bank AGSet Price TargetBuy$78.00View Rating Details
3/2/2015Stifel NicolausDowngradeBuy -> Hold$66.00View Rating Details
3/2/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
12/9/2014LaidlawBoost Price Target$65.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-1.01 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.50)($0.45)($0.48)
Q3 20162($0.02)$0.18$0.08
Q4 20162($0.29)($0.08)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 89.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline
finance.yahoo.com logoIonis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (NASDAQ:IONS)
finance.yahoo.com - September 28 at 10:31 AM
smarteranalyst.com logoPiper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - September 27 at 10:17 AM
fool.com logo3 Stocks That Could Make You Rich (NASDAQ:IONS)
www.fool.com - September 27 at 10:17 AM
4-traders.com logoBiogen : Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy (NASDAQ:IONS)
www.4-traders.com - September 26 at 5:46 PM
smarteranalyst.com logoPiper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing (NASDAQ:IONS)
www.smarteranalyst.com - September 26 at 5:46 PM
News IconHC Trending Hot Stocks! Amphastar Pharmaceuticals Inc (AMPH), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS)
sharemarketupdates.com - September 26 at 10:16 AM
biz.yahoo.com logoIONIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:IONS)
biz.yahoo.com - September 23 at 5:20 PM
News IconIonis Pharmaceuticals Inc (NASDAQ:IONS) & Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Watch List - Money News (NASDAQ:IONS)
www.newsismoney.com - September 23 at 8:36 AM
News IconIonis Pharmaceuticals Inc (NASDAQ:IONS) & Goodyear Tire & Rubber Co (NASDAQ:GT) Watch List - Money News (NASDAQ:IONS)
www.newsismoney.com - September 23 at 8:36 AM
smarteranalyst.com logoStock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc's Akcea Announces Publication in The Lancet of Clinical ... - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - September 23 at 8:36 AM
streetinsider.com logoIonis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data (NASDAQ:IONS)
www.streetinsider.com - September 22 at 3:42 PM
News IconAkcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Dise... (NASDAQ:IONS)
www.advfn.com - September 22 at 3:42 PM
investopedia.com logoBiogen Bets on Nusinersen (BIIB, IONS) (NASDAQ:IONS)
www.investopedia.com - September 22 at 3:42 PM
News IconAnalysts Take the Wheel on Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:IONS)
friscofastball.com - September 22 at 8:52 AM
streetinsider.com logoIonis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data - StreetInsider.com (NASDAQ:IONS)
www.streetinsider.com - September 22 at 8:52 AM
publicnow.com logoAkcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease (NASDAQ:IONS)
www.publicnow.com - September 22 at 8:51 AM
marketrealist.com logoMoves in Cancer Therapeutics among Recent Developments for Ionis (NASDAQ:IONS)
marketrealist.com - September 22 at 8:51 AM
News IconStock on the Move- Ionis Pharmaceuticals, Inc.'s (IONS) - Hot Stocks Point (NASDAQ:IONS)
www.hotstockspoint.com - September 21 at 3:53 PM
News IconConcerns Diverting Active Stocks Direction: Medtronic (NYSE:MDT), Ionis Pharmaceuticals, Inc. (IONS), AmSurg (AMSG) - Street Wise Report (press release) (blog) (NASDAQ:IONS)
streetwisereport.com - September 16 at 9:35 AM
seekingalpha.com logoIonis Pharmaceuticals' (IONS) Management presents at 2016 Wells Fargo Healthcare Brokers Conference Transcript - Seeking Alpha (NASDAQ:IONS)
seekingalpha.com - September 15 at 6:05 PM
capitalcube.com logoETF’s with exposure to Ionis Pharmaceuticals, Inc. : September 15, 2016 (NASDAQ:IONS)
www.capitalcube.com - September 15 at 6:05 PM
News IconCould Ionis Pharmaceuticals Inc Decline After Today's Huge Increase? - Chester News (NASDAQ:IONS)
www.chesterindependent.com - September 15 at 8:52 AM
publicnow.com logoAkcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome (NASDAQ:IONS)
www.publicnow.com - September 15 at 8:52 AM
News IconHC Stocks Impression= Cytori Therapeutics Inc (CYTX), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS)
sharemarketupdates.com - September 14 at 9:53 AM
capitalcube.com logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 12, 2016 (NASDAQ:IONS)
www.capitalcube.com - September 14 at 9:53 AM
capitalcube.com logoIonis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : September 13, 2016 (NASDAQ:IONS)
www.capitalcube.com - September 14 at 9:53 AM
News IconJefferies Group Increases Adeptus Health Inc. (ADPT) Price Target to $100.00 (NASDAQ:IONS)
myhealthbowl.com - September 9 at 5:26 PM
finance.yahoo.com logoIonis Pharmaceuticals, Inc. (IONS) (NASDAQ:IONS)
finance.yahoo.com - September 7 at 9:04 AM
bizjournals.com logoResearch Reports on Healthcare Equities -- Endo, Teva Pharma Industries, Ionis Pharma, and Catalent (NASDAQ:IONS)
www.bizjournals.com - September 7 at 9:04 AM
News IconNews Analysis Report: Ionis Pharmaceuticals Inc (NASDAQ:IONS), LyondellBasell Industries NV(NYSE:LYB), Mattel ... - NYSE Journal (press release) (NASDAQ:IONS)
stockznews.com - September 6 at 10:25 AM
capitalcube.com logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 2, 2016 (NASDAQ:IONS)
www.capitalcube.com - September 2 at 10:28 AM
News IconUpcoming Earnings Report: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - The Voice Registrar (NASDAQ:IONS)
voiceregistrar.com - September 1 at 5:32 PM
News Icon$IONS & $KOS - Ionis Pharmaceuticals Inc (NASDAQ:IONS) & Kosmos Energy Ltd (NYSE:KOS) Stocks in the Spotlight - Money News (NASDAQ:IONS)
www.newsismoney.com - September 1 at 5:32 PM
4-traders.com logoIonis Pharmaceuticals : to Present at Upcoming Investor Conferences (NASDAQ:IONS)
www.4-traders.com - September 1 at 8:38 AM
News IconTraders Recap: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Prudential Financial Inc (NYSE:PRU), Home Depot Inc ... - NYSE Journal (press release) (NASDAQ:IONS)
stockznews.com - August 30 at 8:52 AM
istreetwire.com logoEquities Trend Analysis: Ionis Pharmaceuticals, Inc. (IONS), Coach ... - iStreetWire (NASDAQ:IONS)
istreetwire.com - August 26 at 5:31 PM
News IconStocks in the News: Oclaro, Inc. (NASDAQ:OCLR), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - NYSE Journal (press release) (NASDAQ:IONS)
stockznews.com - August 25 at 10:41 AM
News IconIonis Pharmaceuticals, Inc.'s (IONS): Momentum Stock in Focus - Hot Stocks Point (NASDAQ:IONS)
www.hotstockspoint.com - August 25 at 10:41 AM
istreetwire.com logoStocks Highlights: Danaher (DHR), Ionis Pharmaceuticals (IONS), Capital One Financial (COF) - iStreetWire (NASDAQ:IONS)
istreetwire.com - August 23 at 10:02 AM
News IconIonis Pharmaceuticals Inc. (NASDAQ: IONS) Outperform Rating Reiterated at Wells Fargo & Co. - BNB Daily (blog) (NASDAQ:IONS)
www.baseball-news-blog.com - August 23 at 10:02 AM
4-traders.com logoISIS Pharmaceuticals : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS)
www.4-traders.com - August 22 at 10:16 AM
publicnow.com logoIonis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS)
www.publicnow.com - August 22 at 10:16 AM
News IconThe Key Numbers To Watch From Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)'s Earnings - The Voice Registrar (NASDAQ:IONS)
voiceregistrar.com - August 19 at 8:38 AM
News IconIonis Pharmaceuticals Inc. (NASDAQ: IONS) Overweight Rating Reiterated at Piper Jaffray Cos. - BNB Daily (blog) (NASDAQ:IONS)
www.baseball-news-blog.com - August 19 at 8:38 AM
smarteranalyst.com logoWells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here's Why - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 19 at 8:38 AM
smarteranalyst.com logoWells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here’s Why (NASDAQ:IONS)
www.smarteranalyst.com - August 18 at 5:41 PM
finance.yahoo.com logoIONIS PHARMACEUTICALS INC Financials (NASDAQ:IONS)
finance.yahoo.com - August 18 at 5:41 PM
fool.com logoIonis Pharmaceuticals Inc Begins to Shift Focus (NASDAQ:IONS)
www.fool.com - August 16 at 5:50 PM
smarteranalyst.com logoPiper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 16 at 12:19 PM
smarteranalyst.com logoPiper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead (NASDAQ:IONS)
www.smarteranalyst.com - August 15 at 9:13 PM

Social

Ionis Pharmaceuticals (NASDAQ:IONS) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff